About the Curry Lab
Professor of Medicine, Harvard Medical School
Michael Curry, MD, is a leading investigator on many clinical trials in complications of liver disease including decompensated liver cirrhosis, hepatorenal syndrome, and in HCV cirrhosis.
Dr. Curry was the lead author in a seminal publication on the use of new direct acting antiviral agents (DAAs) in liver transplant candidates to prevent re-infection after liver transplantation and in reversing liver failure from HCV with antiviral therapies. He and his colleagues have developed a web based calculator that can predict the possibility of improving liver function with HCV treatment. Dr. Curry has also performed several studies aiming to study and improve the quality of life of liver transplant patients including the use of antiviral medications to eradicate hepatitis C and the use of calcineurin inhibitor sparing regimens to prevent kidney failure in transplant recipients. He has been a lead author in the therapeutic studies of terlipressin for hepatorenal syndrome (HRS) and has ongoing research to optimize the safety of patients receiving treatment for HRS.